22nd Sleep Well - I am buying this 50% 3yr forward growth platform at 15x earnings
Essential product that is turning into a platform and winning over industry incumbents, no competition (for now).
The 22nd sleep-well pick has had a stellar run so far this year, up multiple times; however, I think this business development is so good that shares are still cheap at the current level.
This isn’t a typical compounder.
It offers a rare combination of triple-digit free cash flow growth and sleep-well qualities that can buffer against future adversity.
My first goal remains protecting our capital, but it doesn’t have to come at the expense of a lower return. This one has the most upside potential of all my picks with fading risks.
SWIs members can expect:
high reinvestment opportunities with 50% returns on investments (ROIC)
aligned management with high ownership and execution
mission-critical products to slow to change end-users
unfocused competition and high barriers to entry
squeaky clean balance sheet
low valuation
fading risks
If you are new, read more about us here, and our latest portfolio review here.